$65.00
Manufacturer: San-Marino
Primary and secondary carnitine insufficiency in adults and children, including newborns and infants. Secondary carnitine insufficiency in patients undergoing hemodialysis. Suspicion of secondary carnitine insufficiency in patients undergoing hemodialysis in the following cases: severe and persistent muscle spasms and / or hypotensive episodes during dialysis; energy deficit, which leads to a significant negative impact on the quality of life; muscle weakness and / or myopathy; cardiopathy; anemia that does not respond to treatment with erythropoietin or requires high doses of erythropoietin; loss of muscle mass.
Description
LECARNITA COMPOSITION
active substance: levocarnitine 1 ml contains 200 mg levocarnitine
auxiliary substances: diluted hydrochloric acid, water for injection.
LECARNITA INDICATIONS
Primary and secondary carnitine deficiency in adults and children, incl. newborns and babies.
Secondary carnitine deficiency in patients undergoing hemodialysis.
Suspected secondary carnitine deficiency in patients undergoing hemodialysis in the following cases:
severe and persistent muscle spasms and / or hypotensive episodes during dialysis
energy deficiency, which leads to a significant negative impact on the quality of life
muscle weakness and / or myopathy
cardiopathy
anemia, does not respond to erythropoietin treatment, or requires high doses of erythropoietin
loss of muscle mass.
LECARNITA CONTRAINDICATIONS
Hypersensitivity to the components of the drug.
LECARNITA DOSAGE AND APPLICATION
Solution for injection is administered by slow injection (2-3 minutes) or infusion.
Application for congenital metabolic disorders.
During therapy, it is advisable to control the level of carnitine and acyl-carnitine in both blood plasma and urine.
The required dose depends on the specificity of the congenital metabolic disorder and the severity of the manifestations of the disease.
In the case of acute decompensation, the recommended dose may be up to 100 mg / kg per day in 3-4 injections. Higher doses can be used if necessary, although side effects such as diarrhea may increase.
Secondary carnitine deficiency in patients undergoing hemodialysis.
Before starting therapy with Lecarnita, it is advisable to control the level of carnitine in the blood plasma. Secondary carnitine deficiency is diagnosed when the ratio of acylcarnitine to free carnitine in blood plasma is more than 0.4 and / or when the concentration of free carnitine is less than 20 μmol / L.
A dose of 2 g should be injected intravenously at the end of each dialysis session. The overall response should be determined by monitoring plasma levels of acylcarnitine and free carnitine and evaluating the patient’s condition. Normalization of the carnitine content in muscle tissue and cardiomyocytes occurs approximately 3 months after reaching the normal concentration of carnitine in the blood plasma. If the introduction of carnitine is stopped, its level will certainly begin to decline again. The need for a repeated saturating course of treatment is determined by quantitative determination of carnitine in blood plasma at regular intervals and by monitoring the patient’s condition.
Hemodialysis is a supportive therapy.
After saturating the course of administration of levocarnitine, a maintenance dose is used – 1 g of levocarnitine per day orally. On the day of dialysis, the drug Lekarnita is used intravenously at a dose of 1 g immediately after the end of the next session.
CHILDREN
The drug is used in children from the first day of life, including premature babies.
Recent Reviews